Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –

– Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Further –

Read more at prnewswire.com